吉非替尼联合盐酸安罗替尼一线治疗EGFR突变晚期非小细胞肺癌的临床研究  

Clinical Study of Gefitinib Combined with Anlotinib Hydrochloride in the First-line Treatment of EGFR Mutation Advanced Non-small Cell Lung Cancer

作　　者：季洪波[1] 王乐乐[1] 商迪[1] 尹胜杰[1] 王晓颖[1] 孙丽立 于海波 高志艳 马晓云 王磊[1] JI Hongbo;WANG Lele;SHANG Di;YIN Shengjie;WANG Xiaoying;SUN Lili;YU Haibo;GAO Zhiyan;MA Xiaoyun;WANG Lei(Chifeng Hospital,Chifeng 024000,China)

机构地区：[1]赤峰市医院,内蒙古赤峰024000

出　　处：《中外医学研究》2020年第28期37-39,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

基　　金：北京医卫健康公益基金会医学科学研究基金资助项目(F1185B)。

摘　　要：目的:探讨吉非替尼联合盐酸安罗替尼一线治疗EGFR突变晚期非小细胞肺癌(NSCLC)的临床效果。方法:回顾性分析笔者所在医院肿瘤内科2018年1-12月收治的30例EGFR突变晚期NSCLC患者的临床资料,所有患者均予以吉非替尼联合盐酸安罗替尼一线治疗。观察临床疗效及治疗前后肿瘤标志物水平、血清脂肪酸合成酶(FAS)及肿瘤型M2丙酮酸激酶(TuM2-PK)及不良反应发生率及1年生存率。结果:30例患者中总缓解24例,总缓解率为80.00%。治疗后,患者血清癌抗原125(CA125)、癌胚抗原(CEA)、细胞角蛋白19片段抗原(CYFRA21-1)及神经烯醇化酶(NSE)水平、FAS及TuM2-PK水平均较治疗前明显降低,差异有统计学意义(P<0.05)。30例患者中共9例发生不良反应,不良反应发生率为30%;30例患者化疗结束后1年生存26例,生存率为86.67%。结论:EGFR突变晚期NSCLC患者采用吉非替尼联合盐酸安罗替尼一线治疗的效果确切,可有效缓解病症,显著改善肿瘤标志物水平,降低FAS及TuM2-PK水平,且远期生存率较高,值得临床推广使用。Objective:To investigate the clinical effect of Gefitinib combined with Anlotinib Hydrochloride in the first-line treatment of EGFR mutation advanced non-small cell lung cancer (NSCLC).Method:The clinical data of 30 patients with EGFR mutation advanced NSCLC admitted in the department of medical oncology of our hospital from January to December 2018 were retrospectively analyzed.All patients were treated with Gefitinib combined with Anlotinib Hydrochloride in the first-line treatment.The clinical efficacy,tumor marker level,serum fatty acid synthase (FAS) and tumor M2 pyruvate kinase (TUM2-PK) before and after treatment,incidence of adverse reaction and 1-year survival rate were observed.Result:Among the 30 patients,there were 24 cases with total remission,and the total remission rate was 80.00%.After treatment,the serum levels of carbohydrate antigen 125 (CA125),carcinoembryonic antigen (CEA),cytokeratin fragment 19 (CYFRA21-1) and neuron-specific enolase (NSE),FAS and TuM2-PK were significantly lower than those before treatment,the differences were statistically significant (P<0.05).There were 9 cases of adverse reactions in 30 cases,the incidence of adverse reactions was 30%.Twenty-six of the 30 patients survived 1 year after chemotherapy,with a survival rate of 86.67%.Conclusion:The first-line treatment effect of Gefitinib combined with Anlotinib Hydrochloride in EGFR mutation advanced NSCLC patients is definite,which can effectively relieve the disease symptoms,significantly improve the level of tumor markers,reduce the levels of FAS and TuM2-PK,and has a high long-term survival rate,which is worthy of clinical promotion.

关 键 词：非小细胞肺癌 吉非替尼 盐酸安罗替尼 肿瘤标志物 远期疗效 

分 类 号：R734.2[医药卫生—肿瘤]